1. Home
  2. EVO vs MNKD Comparison

EVO vs MNKD Comparison

Compare EVO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • MNKD
  • Stock Information
  • Founded
  • EVO 1993
  • MNKD 1991
  • Country
  • EVO Germany
  • MNKD United States
  • Employees
  • EVO N/A
  • MNKD N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVO Health Care
  • MNKD Health Care
  • Exchange
  • EVO Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • EVO 1.4B
  • MNKD 1.7B
  • IPO Year
  • EVO 2021
  • MNKD 2004
  • Fundamental
  • Price
  • EVO $4.15
  • MNKD $5.47
  • Analyst Decision
  • EVO Strong Buy
  • MNKD Strong Buy
  • Analyst Count
  • EVO 1
  • MNKD 5
  • Target Price
  • EVO $7.00
  • MNKD $10.80
  • AVG Volume (30 Days)
  • EVO 42.9K
  • MNKD 4.7M
  • Earning Date
  • EVO 11-05-2025
  • MNKD 11-05-2025
  • Dividend Yield
  • EVO N/A
  • MNKD N/A
  • EPS Growth
  • EVO N/A
  • MNKD 149.32
  • EPS
  • EVO N/A
  • MNKD 0.11
  • Revenue
  • EVO $912,894,891.00
  • MNKD $301,736,000.00
  • Revenue This Year
  • EVO N/A
  • MNKD $14.78
  • Revenue Next Year
  • EVO $10.78
  • MNKD $19.36
  • P/E Ratio
  • EVO N/A
  • MNKD $51.20
  • Revenue Growth
  • EVO N/A
  • MNKD 21.48
  • 52 Week Low
  • EVO $2.84
  • MNKD $3.38
  • 52 Week High
  • EVO $5.64
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • EVO 63.61
  • MNKD 53.22
  • Support Level
  • EVO $4.05
  • MNKD $5.24
  • Resistance Level
  • EVO $4.27
  • MNKD $5.67
  • Average True Range (ATR)
  • EVO 0.09
  • MNKD 0.21
  • MACD
  • EVO 0.01
  • MNKD -0.01
  • Stochastic Oscillator
  • EVO 73.91
  • MNKD 73.84

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: